Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma.

Hillier K, Hughes A, Shamberger RC, Shusterman S, Perez-Atayde AR, Wassner AJ, Iafrate AJ, Dubuc A, Janeway KA, Rothenberg SM, Cox MC, Randolph GW, Wirth LJ, Tsai H, Church A, DuBois SG.

Thyroid. 2019 Nov;29(11):1704-1707. doi: 10.1089/thy.2019.0041.

PMID:
31650892
2.

Technikbereitschaft in der ambulanten Pflege.

Hülsken-Giesler M, Daxberger S, Peters M, Wirth LM.

Pflege. 2019;32(6):334-342. doi: 10.1024/1012-5302/a000702. Epub 2019 Oct 23.

PMID:
31640473
3.

Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples.

Angell TE, Wirth LJ, Cabanillas ME, Shindo ML, Cibas ES, Babiarz JE, Hao Y, Kim SY, Walsh PS, Huang J, Kloos RT, Kennedy GC, Waguespack SG.

Front Endocrinol (Lausanne). 2019 Sep 11;10:612. doi: 10.3389/fendo.2019.00612. eCollection 2019.

4.

Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.

Ishida E, Lee J, Campbell JS, Chakravarty PD, Katori Y, Ogawa T, Johnson L, Mukhopadhyay A, Faquin WC, Lin DT, Wirth LJ, Pierce RH, Pai SI.

Cancer Immunol Immunother. 2019 Aug;68(8):1273-1286. doi: 10.1007/s00262-019-02357-1. Epub 2019 Jun 26.

PMID:
31243491
5.

Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.

Ameri AH, Mooradian MJ, Emerick KS, Park JC, Wirth LJ, Asgari MM, Tsao H, Lawrence D, Sullivan RJ, Demehri S.

Br J Dermatol. 2019 Nov;181(5):1095-1097. doi: 10.1111/bjd.18144. Epub 2019 Aug 7. No abstract available.

PMID:
31102460
6.

Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How?

Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:364-372. doi: 10.1200/EDBK_238315. Epub 2019 May 17. Review.

7.

Yearly Treatment Patterns for Patients with Recently Diagnosed Diabetic Macular Edema.

Moulin TA, Adjei Boakye E, Wirth LS, Chen J, Burroughs TE, Vollman DE.

Ophthalmol Retina. 2019 Apr;3(4):362-370. doi: 10.1016/j.oret.2018.11.014. Epub 2018 Dec 7.

PMID:
31014689
8.

Expanding Access to Cancer Clinical Trials for Patients With Mental Illness.

Irwin KE, Moy B, Fields LE, Callaway CA, Park ER, Wirth L.

J Clin Oncol. 2019 Jun 20;37(18):1524-1528. doi: 10.1200/JCO.18.01881. Epub 2019 Apr 15. No abstract available.

9.

Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.

Thierauf J, Ramamurthy N, Jo VY, Robinson H, Frazier RP, Gonzalez J, Pacula M, Dominguez Meneses E, Nose V, Nardi V, Dias-Santagata D, Le LP, Lin DT, Faquin WC, Wirth LJ, Hess J, Iafrate AJ, Lennerz JK.

Oncologist. 2019 Oct;24(10):1356-1367. doi: 10.1634/theoncologist.2018-0515. Epub 2019 Mar 29.

PMID:
30926674
10.

Response to Letter to the Editor: New Insights and Old Questions in Acute Stroke Blood Pressure Control.

Nasi LA, Martins SCO, Rebello LC, Gus M, Weiss G, de Almeida AG, Brondani R, DalPizzol A, Fuchs FD, Valença MJM, Wirth LF, Nunes G, Anderson CS.

Neurocrit Care. 2019 Jun;30(3):698-699. doi: 10.1007/s12028-019-00683-x. No abstract available.

PMID:
30809757
11.

Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy.

Koenigs MB, Lefranc-Torres A, Bonilla-Velez J, Patel KB, Hayes DN, Glomski K, Busse PM, Chan AW, Clark JR, Deschler DG, Emerick KS, Hammon RJ, Wirth LJ, Lin DT, Mroz EA, Faquin WC, Rocco JW.

J Natl Cancer Inst. 2019 Sep 1;111(9):933-942. doi: 10.1093/jnci/djy224.

PMID:
30715409
12.

NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018.

Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA.

J Natl Compr Canc Netw. 2018 Dec;16(12):1429-1440. doi: 10.6004/jnccn.2018.0089.

PMID:
30545990
13.

Geographic variations in racial disparities in postmastectomy breast reconstruction: A SEER database analysis.

Wirth LS, Hinyard L, Keller J, Bucholz E, Schwartz T.

Breast J. 2019 Jan;25(1):112-116. doi: 10.1111/tbj.13166. Epub 2018 Dec 9.

PMID:
30536478
14.

Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.

Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S.

Int J Cancer. 2019 May 1;144(9):2266-2278. doi: 10.1002/ijc.32041. Epub 2019 Jan 24.

PMID:
30515783
15.

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.

Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A.

Eur J Cancer. 2019 Jan;106:61-68. doi: 10.1016/j.ejca.2018.10.002. Epub 2018 Nov 22.

16.

Still Perfecting Radioiodine in Thyroid Cancer, After All These Years.

Wirth LJ.

J Clin Endocrinol Metab. 2019 May 1;104(5):1655-1657. doi: 10.1210/jc.2018-02437. No abstract available.

PMID:
30462299
17.

Early Manipulation of Arterial Blood Pressure in Acute Ischemic Stroke (MAPAS): Results of a Randomized Controlled Trial.

Nasi LA, Martins SCO, Gus M, Weiss G, de Almeida AG, Brondani R, Rebello LC, DalPizzol A, Fuchs FD, Valença MJM, Wirth LF, Nunes G, Anderson CS.

Neurocrit Care. 2019 Apr;30(2):372-379. doi: 10.1007/s12028-018-0642-5.

PMID:
30460598
18.

Controversies Regarding the Management of Locoregionally Advanced Nasopharyngeal Carcinoma: Are We Asking the Right Questions?

Park JC, Chan AW, Wirth LJ.

J Oncol Pract. 2018 Oct;14(10):603-605. doi: 10.1200/JOP.18.00529. No abstract available.

PMID:
30312565
19.

Liminality as a dimension of the experience of living with terminal cancer.

Willig C, Wirth L.

Palliat Support Care. 2019 Jun;17(3):333-337. doi: 10.1017/S1478951518000536. Epub 2018 Sep 6.

PMID:
30187842
20.

Patients' experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study.

Degboe A, Knight SL, Halling K, Trigg A, Al-Zubeidi T, Aldhouse N, Kitchen H, Wirth L, Rogers SN.

J Patient Rep Outcomes. 2018 Aug 1;2:33. doi: 10.1186/s41687-018-0060-7. eCollection 2017.

21.

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG.

Cancer Cell. 2018 Aug 13;34(2):242-255.e5. doi: 10.1016/j.ccell.2018.06.013.

22.

Selective RET kinase inhibition for patients with RET-altered cancers.

Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A.

Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.

23.

Correlates of health information seeking between adults diagnosed with and without cancer.

Adjei Boakye E, Mohammed KA, Geneus CJ, Tobo BB, Wirth LS, Yang L, Osazuwa-Peters N.

PLoS One. 2018 May 10;13(5):e0196446. doi: 10.1371/journal.pone.0196446. eCollection 2018.

24.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK.

Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.

25.

Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).

Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M.

Cancer. 2018 Jun 1;124(11):2365-2372. doi: 10.1002/cncr.31344. Epub 2018 Apr 14.

26.

Oncologic and functional outcomes of pretreatment tracheotomy in advanced laryngeal squamous cell carcinoma: A multi-institutional analysis.

Byrd SA, Xu MJ, Cass LM, Wehrmann DJ, Naunheim M, Christopher K, Dombrowski JJ, Walker RJ, Wirth L, Clark J, Busse P, Chan A, Deschler DG, Emerick K, Lin DT, Varvares MA.

Oral Oncol. 2018 Mar;78:171-176. doi: 10.1016/j.oraloncology.2018.01.018. Epub 2018 Feb 20.

PMID:
29496047
27.

Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer.

Addison D, Lawler PR, Emami H, Janjua SA, Staziaki PV, Hallett TR, Hennessy O, Lee H, Szilveszter B, Lu M, Mousavi N, Nayor MG, Delling FN, Romero JM, Wirth LJ, Chan AW, Hoffmann U, Neilan TG.

J Stroke. 2018 Jan;20(1):71-79. doi: 10.5853/jos.2017.01802. Epub 2018 Jan 31.

28.

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S.

Thyroid. 2018 Mar;28(3):328-339. doi: 10.1089/thy.2017.0322. Epub 2018 Feb 27.

29.

A meta-synthesis of studies of patients' experience of living with terminal cancer.

Willig C, Wirth L.

Health Psychol. 2018 Mar;37(3):228-237. doi: 10.1037/hea0000581. Epub 2018 Jan 25.

PMID:
29369679
30.

Desmoid Tumours of the extremity and trunk. A retrospective study of 44 patients.

Wirth L, Klein A, Baur-Melnyk A, Knösel T, Lindner LH, Roeder F, Jansson V, Dürr HR.

BMC Musculoskelet Disord. 2018 Jan 5;19(1):2. doi: 10.1186/s12891-017-1924-3.

31.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.

32.

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.

Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S.

Ann Oncol. 2017 Nov 1;28(11):2813-2819. doi: 10.1093/annonc/mdx479.

33.

PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs.

Mattox AK, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng YC, Chen H, Poznansky MC, Iyengar NM, Pai SI.

Cancer Res. 2017 Nov 15;77(22):6365-6374. doi: 10.1158/0008-5472.CAN-16-3453. Epub 2017 Sep 25.

34.

Human Papillomavirus Status and the Risk of Cerebrovascular Events Following Radiation Therapy for Head and Neck Cancer.

Addison D, Seidelmann SB, Janjua SA, Emami H, Staziaki PV, Hallett TR, Szilveszter B, Lu MT, Cambria RP, Hoffmann U, Chan AW, Wirth LJ, Neilan TG.

J Am Heart Assoc. 2017 Aug 30;6(9). pii: e006453. doi: 10.1161/JAHA.117.006453.

35.

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH.

J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17.

36.

Foreign-born blacks no different from whites for odds of stroke.

Wirth LS, Tobo BB, Hinyard L, Vaughn MG.

J Epidemiol Community Health. 2017 Aug;71(8):786-793. doi: 10.1136/jech-2016-208125. Epub 2017 Jun 28.

PMID:
28659387
37.

Bone marrow-on-a-chip: Long-term culture of human haematopoietic stem cells in a three-dimensional microfluidic environment.

Sieber S, Wirth L, Cavak N, Koenigsmark M, Marx U, Lauster R, Rosowski M.

J Tissue Eng Regen Med. 2018 Feb;12(2):479-489. doi: 10.1002/term.2507. Epub 2017 Nov 5.

PMID:
28658717
38.

Race is a Strong Predictor of Receipt of a Written Survivorship Care Plan: Results from the National Health Interview Survey.

Hinyard L, Wirth LS.

J Community Health. 2017 Dec;42(6):1156-1162. doi: 10.1007/s10900-017-0365-0.

PMID:
28455672
39.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.

40.

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.

Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH.

Cancer. 2017 Jul 15;123(14):2642-2650. doi: 10.1002/cncr.30541. Epub 2017 Feb 21.

41.

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI.

Endocrine. 2017 Apr;56(1):121-128. doi: 10.1007/s12020-017-1233-5. Epub 2017 Feb 3.

42.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
43.

The effect of marital status on breast cancer-related outcomes in women under 65: A SEER database analysis.

Hinyard L, Wirth LS, Clancy JM, Schwartz T.

Breast. 2017 Apr;32:13-17. doi: 10.1016/j.breast.2016.12.008. Epub 2016 Dec 22.

PMID:
28012410
44.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.

Front Oncol. 2016 Oct 31;6:232. eCollection 2016.

45.

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer.

Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M.

J Clin Endocrinol Metab. 2016 Nov;101(11):4103-4109. Epub 2016 Aug 22.

46.

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.

Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S.

Oral Oncol. 2016 Oct;61:31-40. doi: 10.1016/j.oraloncology.2016.07.005. Epub 2016 Aug 20.

PMID:
27688102
47.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

48.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM.

Cancer. 2016 Dec 15;122(24):3803-3811. doi: 10.1002/cncr.30256. Epub 2016 Aug 15.

49.

Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.

Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS.

Cancer. 2016 Dec 15;122(24):3856-3864. doi: 10.1002/cncr.30252. Epub 2016 Aug 15.

50.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ.

Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.

Supplemental Content

Support Center